Which is better, Selank or Semax?
Selank and Semax are researched for different contexts, so the better choice depends on study goals, mechanism priorities, and protocol design.
Compare Selank and Semax: dosing, mechanisms, safety profiles, and research evidence. Citation-backed comparison.
A comparison of Selank and Semax as Russian neuropeptides, covering mechanism differences, anxiolytic vs. cognitive focus, evidence context, and administration research.
Selank and Semax are both Russian-developed neuropeptides that have received regulatory approval in Russia for neurological and psychiatric applications, but they are studied for different primary mechanisms and research questions. Selank is more commonly framed as an anxiolytic compound, while Semax is more often discussed in neuroprotective and cognitive enhancement contexts.
Selank is a synthetic heptapeptide analog of the endogenous tuftsin molecule, studied for modulation of IL-6, enkephalins, and anxiolytic signaling without benzodiazepine receptor activity. Semax is a synthetic analog of the ACTH 4-7 fragment, studied for BDNF upregulation, neuroprotective effects following ischemia, and cognitive enhancement in experimental settings.
Both compounds are commonly studied via intranasal administration, which is the primary route in Russian clinical research. This makes them somewhat unusual in the research peptide landscape, where subcutaneous injection is the more standard route. Intranasal delivery is discussed as enabling direct CNS exposure, and most published protocols for both compounds reflect this route.
Both compounds have more published literature in Russian-language journals than in English-indexed databases, which makes direct evidence review more difficult for Western researchers. Semax has been studied more extensively in stroke and neuroprotection models, while Selank evidence is more concentrated in anxiety and immune-regulation research. PeptaBase includes both with their available citation context.
Selank and Semax are researched for different contexts, so the better choice depends on study goals, mechanism priorities, and protocol design.
Some researchers evaluate Selank and Semax together, but combination design depends on evidence quality, safety considerations, and whether overlapping mechanisms are appropriate for the research question.
The main differences are mechanism, dosing cadence, evidence maturity, and safety profile emphasis in the published literature.